Showing 1071-1080 of 10592 results for "".
Detecting Multiple Sclerosis Earlier: PRLs and the Evolving McDonald Diagnostic Criteria
https://reachmd.com/diseases-diagnoses/ms-immune-disorders/detecting-multiple-sclerosis-earlier-prls-and-the-evolving-mcdonald-diagnostic-criteria/54390/This episode explores new evidence showing that paramagnetic rim lesions (PRLs) are highly prevalent early in multiple sclerosis (MS) and can differentiate MS from mimics with striking accuracy. Daniel Ontaneda, MD, PhD, Cleveland Clinic Lerner College of Medicine, Cleveland, OH, and Pascal Sati, Ph“We have the opportunity to understand what happens when someone leaves the clinic,” says Dr. Rajiv Kumar of Apple and Stanford Medicine
https://reachmd.com/programs/the-convergence/rajiv-kumar-apple-stanford/54782/Consumer health data can reshape how clinicians stay connected to patients and support them between visits—but only if we use it effectively. Dr. Brian McDonough is joined by Dr. Rajiv Kumar, a physician-researcher at Apple and Adjunct Clinical Professor of Pediatric Endocrinology and Diabetes at StThe Future of IgA Nephropathy: Why Biomarkers Matter
https://reachmd.com/programs/frontlines-iga-nephropathy/the-future-of-iga-nephropathy-why-biomarkers-matter/26942/Dive into the importance of biomarkers in the intensifying pursuit of newer, more effective treatments for IgA nephropathy.The Lp(a)-Lowering Landscape: Navigating Current and Future Therapeutic Options
https://reachmd.com/clinical-practice/cardiology/the-lpa-lowering-landscape-navigating-current-and-future-therapeutic-options/39970/Explore new and emerging therapies transforming Lp(a) and SHTG management—why staying current in lipid care has never been more essential.Advancing MS Care with Multimodal Aging Signatures and Proteomic Biomarkers
https://reachmd.com/programs/neurofrontiers/ms-multimodal-aging-signatures-proteomic-biomarkers/54241/Multimodal aging signatures are reshaping our understanding of progression and prognosis in multiple sclerosis (MS). Host Ryan Quigley sits down with Dr. Adil Harroud and Mr. Dylan Hamitouche to learn more about implications for the future of risk stratification and personalized treatment in MS,Gastric Cancer Screening & Surveillance Strategies
https://reachmd.com/programs/gi-insights/gastric-cancer-screening-surveillance-strategies/12644/With no current guidelines available for gastric cancer, how can we screen and better detect early gastrointestinal malignancies?Benefit/Risk Strategies in Selecting Therapeutic Solutions for MS
https://reachmd.com/programs/global-neurology-academy/benefitrisk-strategies-selecting-therapeutic-solutions-ms/9535/This lecture was given live at Regional Medical Update Dinner on Current and Future Treatments educational program, held in select European cities. This highly-interactive live educational meeting will provide attendees with the most recent information concerning new and emerging treatment strategieExamining Penile Implants for Surgical Treatment of Erectile Dysfunction
https://reachmd.com/programs/primary-care-today/examining-penile-implants-surgical-treatment-erectile-dysfunction/8200/Dr. Charles Walker shares clinical insights about penile prostheses, such as inflatable versus malleable devices, for treating erectile dysfunction.Why are We Still Spending So Much Money on Healthcare?
https://reachmd.com/programs/primary-care-today/why-are-we-still-spending-so-much-money-on-healthcare/7037/Dr. Brian McDonough welcomes Charles Cleary, President and CEO of Leadership Outcomes, Inc, a healthcare management consulting firm. Mr. Cleary's specialty is in helping healthcare organizations define outcomes to sustain the highest levels of medical & surgical quality care, patient engagement,Cancer Risk of Sitting Down
https://reachmd.com/programs/what-your-patients-are-talking-about/cancer-risk-of-sitting-down/7016/Dr. McDonough discusses how lowering patient sedentary time can prevent precancerous lesions according to a report in the American Association for Cancer Research.